Benjamin Herzberg, MD, discusses unmet needs, immunotherapy sequencing, and referral timing in KRAS-mutant NSCLC.
Benjamin Herzberg, MD
Advertisement
Benjamin Herzberg, MD, is a thoracic medical oncologist at the Herbert Irving Comprehensive Cancer Center at Columbia University.
Articles by Benjamin Herzberg, MD
Benjamin Herzberg, MD, highlights ASCO 2026's most exciting KRAS data, sequencing strategies, and emerging therapies for KRAS-mutant lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Reduced Monitoring Time for First 2 Tarlatamab Doses
2
Landmark ctDNA Testing Offers an Early Window Into Immunotherapy Response in NSCLC
3
Frontline Activity Seen With Zidesamtinib in ROS1+ NSCLC
4
FDA Approves Aminolevulinic Acid Gel With PDT for Superficial Basal Cell Carcinoma
5